CASE REPORT article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1564788
This article is part of the Research TopicBiomarker-Driven Strategies for Personalized Management of Systemic Inflammatory Response SyndromeView all 7 articles
Low Pressure Hyperbaric Oxygen Therapy as a Potential Alternative Treatment for Chronic Inflammatory Response Syndrome: A Case Study with Notable Improvements in Fatigue, Cognition, and Testing.
Provisionally accepted
- Be-Well Medicine LLC, Kenai, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chronic Inflammatory Response Syndrome (CIRS), a complex condition triggered by environmental exposures such as mold toxins, remains challenging to treat effectively. This case study documents the incidental findings of hyperbaric oxygen therapy (HBOT) as a potential therapeutic intervention for CIRS. A 60-year-old female patient with persistent symptoms and abnormal laboratory markers underwent 40 shallow dive HBOT sessions over 10 weeks. Clinical evaluations included symptom scoring, visual contrast sensitivity (VCS) testing, and biomarker analysis, with pre-treatment tests conducted via Quest Diagnostics and post-treatment tests via LabCorp.Results demonstrated significant improvements: resolution of all 22 reported symptoms, normalization of VCS scores (from 68% to 93%), and notable reductions in inflammatory biomarkers, including TGF-β1 and MMP-9. This case illustrates HBOT's ability to modulate systemic inflammation, improve neurocognitive outcomes, and enhance recovery in patients with complex environmental illnesses. While limited to a single-patient design, this study underscores the need for extensive quantitative research to validate HBOT's efficacy in managing CIRS and similar conditions.
Keywords: chronic inflammatory response syndrome, Fatigue, congnition impairment, Cytokines, HB02
Received: 07 Feb 2025; Accepted: 25 Jun 2025.
Copyright: © 2025 Coletti-Giesler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kristen Coletti-Giesler, Be-Well Medicine LLC, Kenai, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.